Ken Griffin Ventyx Biosciences, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.85 - $3.2 $5,365 - $9,280	-2,900 Reduced 10.28%	25,300 $55,000
Q2 2024 Aug 14, 2024	SELL	$2.31 - $5.59 $15,477 - $37,453	-6,700 Reduced 19.2%	28,200 $65,000
Q1 2024 May 15, 2024	BUY	$1.9 - $10.13 $40,470 - $215,769	21,300 Added 156.62%	34,900 $191,000
Q4 2023 Feb 14, 2024	BUY	$2.08 - $31.18 $12,896 - $193,316	6,200 Added 83.78%	13,600 $33,000
Q3 2023 Nov 14, 2023	SELL	$29.8 - $40.3 $187,740 - $253,889	-6,300 Reduced 45.99%	7,400 $257,000
Q2 2023 Aug 14, 2023	SELL	$28.53 - $39.55 $11,412 - $15,819	-400 Reduced 2.84%	13,700 $449,000
Q1 2023 May 15, 2023	SELL	$29.51 - $46.65 $215,423 - $340,545	-7,300 Reduced 34.11%	14,100 $472,000
Q4 2022 Feb 14, 2023	BUY	$24.16 - $36.38 $159,456 - $240,108	6,600 Added 44.59%	21,400 $701,000
Q3 2022 Nov 14, 2022	BUY	$12.64 - $38.7 $187,072 - $572,760	14,800 New	14,800 $517,000

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $128M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.